Preliminary Results of Treatment With Pegylated Interferon Alpha 2A for Chronic Hepatitis C Virus in Kidney Transplant Candidates on Hemodialysis

2007 ◽  
Vol 39 (7) ◽  
pp. 2125-2127 ◽  
Author(s):  
T. Casanovas-Taltavull ◽  
C. Baliellas ◽  
M. Llobet ◽  
J.M. Cruzado ◽  
J. Castellote ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Transplant ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Results Of Treatment ◽  
Chronic Hepatitis C Virus ◽  
Transplant Candidates

scholarly journals Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection

2012 ◽  
Vol 140 (9-10) ◽  
pp. 612-618
Author(s):  
Dragan Delic ◽  
Nikola Mitrovic ◽  
Natasa Popovic ◽  
Aleksandar Urosevic ◽  
Ivana Pesic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Hcv Rna ◽  
Pegylated Interferon Alpha ◽  
Chronic Hepatitis C Virus

Introduction. Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis that causes bleeding from the gastrointestinal tract, liver failure and primary hepatocellular carcinoma. Use of standard therapeutic option consists of recombinant pegylated interferon alpha 2a/b with ribavirin in order to eradicate virus and prevent complications. Objective. The aim of investigation was to evaluate efficiency of combination therapy (pegylated interferon alpha 2a/b plus ribavirin) in patients with chronic HCV infection and to estimate predictive factors for successful treatment. Methods. A total of 387 patients with confirmed diagnosis of hepatitis C were evaluated (aged 18-65 years of both genders). Patients were treated with pegylated interferon alpha 2a/b and ribavirin according to a standard regimen lasting 24 or 48 weeks, dependent on virus genotype. Results. Negative HCV RNA (PCR assay) was recorded in 79.7% of patients at the end of treatment. Six months after completed therapy, negative HCV RNA, i.e. stained virologic response (SVR) was assessed in 70.5% of patients. Statistical summary of our results concerning SVR confirmed better efficiency of combination therapy for the following parameters compared to other investigated variables: age ?40 (84.3% vs. 59.l%; p<0.0005), absence of cirrhosis (75.6% vs. 58.3%; p=0.003), lack of genotype 1 (86.6% vs. 61.8%; p<0.0005), and in patients who received full doses of pegylated interferon alpha 2a (78.3% vs. 63.3%; p=0.002). Conclusion. Combination therapy of recombinant pegylated interferon alpha 2a with ribavirin leads to SVR in the majority of treated patients (70.5%). Successful treatment depends on a variety of host and virus factors.

scholarly journals Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin

2008 ◽  
Vol 198 (6) ◽  
pp. 808-812 ◽  
Author(s):  
James Fung ◽  
Ching‐Lung Lai ◽  
Ivan Hung ◽  
John Young ◽  
Charles Cheng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Virus Genotype ◽  
Chronic Hepatitis C Virus ◽  
Infection Response

scholarly journals Pleuro-Pulmonary Nocardiosis as Opportunistic Infection in a Patient with Chronic Hepatitis C under Combination Treatment with Pegylated Interferon, Ribavirin, and Boceprevir

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Csilla Putz-Bankuti ◽  
Harald H. Kessler ◽  
Thomas Valentin ◽  
Eva Leitner ◽  
Emina Talakic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pulmonary Infection ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus ◽  
Aerobic Actinomycetes

Nocardiosis is an infrequent but serious pulmonary infection caused by Gram-positive aerobic actinomycetes. In this paper, we report on a 48-year-old patient with pleuropulmonary nocardiosis and cirrhosis due to chronic hepatitis C virus infection treated with triple antiviral treatment complicated by prolonged neutropenia.

Sign in / Sign up

Export Citation Format

Share Document